US 11,446,309 B2Granted

Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors

AssigneeDana-Farber Cancer Institute, Inc.

InventorsJames E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen

Life of this patent

Estimating the term…

Abstract

The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.

Claims6

Dependent claims

A method of treating diffuse large B-cell lymphoma (DLBCL) comprising:

administering to a subject in need thereof a first agent, S-JQ35:
or a pharmaceutically acceptable salt thereof,
in combination with one or more second agents selected from ABT263, or ABT199,
wherein the first agent and the one or more second agents are administered in an amount effective to treat the DLBCL.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 15/034,922Filed 7 Nov 2014 · us provisional application
Priority: 8 Nov 2013
Published: US 2016/0279141 A129 Sep 2016
Granted: 20 Sep 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 31/551
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having two nitrogen atoms, e.g. dilazep
A61K 31/404
Condensed with carbocyclic rings, e.g. carbazole: indoles, e.g. pindolol
A61K 31/453
Containing further heterocyclic ring systems: containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol

Family

Application61/901,908Us provisional application · filed 8 Nov 2013
US 2016/0279141 A1Pre-grant publication · published 29 Sep 2016
US 11,446,309 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results